



AMCP Publishes New Pay-for-Performance Principles

On Dec. 14, AMCP announced its support of the use of payment arrangements for pharmacists that include performance-based metrics related to the services they provide. Performance-based arrangements help improve quality care while providing incentives to pharmacies that achieve better health outcomes. AMCP supports value-based payment models that incentivize improvement in patient outcomes. To help guide how such models can be implemented in a way that benefits all parties and, most importantly, improves patient care, the AMCP Board of Directors recently approved a pay-for-performance principles document entitled Performance-Based Reimbursement and Direct and Indirect Remuneration (DIR) Fees. AMCP developed these principles through a member-driven process led by the Public Policy and Professional Practice committees, and they will be the foundation of AMCP's advocacy efforts as federal and state policymakers address performance-based reimbursement going forward.

[Read the principles.](#)



Eye On Washington

AMCP Joins Public Health Leaders in Defense of OSHA's COVID-19 Vaccine Rule

On Dec. 3, AMCP signed on to an amicus brief in support of OSHA's Emergency Temporary Standard on Vaccination and Testing, which is currently being challenged in a case before the U.S. Court of Appeals for the Sixth Circuit. OSHA's emergency order would require 84 million American workers employed by large companies to get vaccinated against COVID-19 or wear a mask at work and get tested regularly effective Jan. 4, 2022. AMCP joined a diverse group of scholars and professional associations dedicated to promoting public health, led by the American Public Health Association.

[Read the amicus brief.](#)

Advocacy Tip

Stay up-to-date: Read AMCP's [Letters, Statements and Analysis](#) on all legislation and regulation impacting managed care pharmacy.

AMCP Supports Dr. Robert Califf's Nomination for FDA Commissioner

On Dec. 8, AMCP sent a letter of support endorsing the nomination of Dr. Robert Califf to serve as Commissioner of the FDA. Dr. Califf previously served as FDA Commissioner during the Obama administration. He is a well-respected clinical trial researcher and an internationally recognized expert in cardiovascular medicine. AMCP stands ready to partner with him as FDA Commissioner on increasing patient access to cost-effective treatments, improving health outcomes, and ensuring health equity for all Americans.

AMCP also signed on to a [letter of support](#) with other pharmacy and health care associations.

[View AMCP's letter of support.](#)

ICYMI: AMCP Quarterly Legislative and Regulatory Briefing Now Available

On Nov. 17, AMCP's Policy and Government Relations team provided a comprehensive update on federal and state legislative and regulatory developments impacting managed care. Staff reviewed the major health care provisions in the Bipartisan Infrastructure and Build Back Better Acts, shared progress on AMCP's federal priority legislation, and examined Congress's year-end timeline. The presentation also provided insight into recent federal regulatory updates and AMCP's priority state legislative issues.

[View the presentation.](#)

Reps. DeGette and Upton Release the Cures 2.0 Act

On Nov. 16, Reps. DeGette and Upton released the Cures 2.0 Act. This legislation aims to speed up the delivery of innovative treatments and therapies by building on the progress made since passage of the original Cures package. This bill would create the Advanced Research Projects Agency for Health (ARPA-H) which is tasked with finding new cures and treatments to a slate of illnesses and will improve clinical trial design and ensure that drug-makers meet post-approval confirmatory study requirements. This bipartisan legislation has 63 cosponsors and was referred to the various committees of jurisdiction. The Cures 2.0 Act is a key part of AMCP's 2022 legislative priorities, and AMCP staff will continue to track this bill as it moves through the legislative

Now
approved in
3 indications

Learn about
the new indications

Brukina[®]
zanobrutinib 10mg capsules

© BeiGene, Ltd. 2021 All Rights Reserved.

process. Be on the lookout for an AMCP grassroots alert this week!

[Read the original sponsors' press release.](#)

AMCP Seeking New Regulatory Affairs Director

AMCP is seeking qualified candidates for the Director, Regulatory Affairs position. This person will be a key member of the Policy & Government Relations team responsible for analyzing, advancing, communicating, and advocating AMCP's regulatory positions within federal and state government agencies, to AMCP members, and other key stakeholders.

[Please see the job posting.](#)

AMCP

675 North Washington Street, Suite 220, Alexandria, VA 22314
703.684.2600 | www.amcp.org

[Manage My Emails](#)